SBI1997 displays anticancer impact in liver
NEW YORK—Saronic Biotechnology Inc., which specializes in developing novel immunotherapies for the treatment of liver cancer, recently published human validation data in the Journal of Immunotherapy supporting the mechanism of action of its lead therapeutic SBI1997, an autologous dendritic cell immunotherapy. The findings appeared in the article “Prognostic Role of Immune Cells in Hepatitis B-associated Hepatocellular Carcinoma Following Surgical Resection Depends on their Localization and Tumor Size.” The paper notes a correlation between high levels of Foxp3, a protein marker for regulatory T cells, and poor overall survival among patients with resectable hepatocellular carcinoma. Preclinical testing of SBI1997 showed a noticeable anticancer impact and a reduction in the levels of immunosuppressive regulatory T cells in the tumor microenvironment. Saronic intends to kick off a randomized Phase 1/2 clinical trial of the compound this year.